Pegram MD - Search Results

1

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ. Aguilar Z, et al. Among authors: pegram md. Oncogene. 1999 Oct 28;18(44):6050-62. doi: 10.1038/sj.onc.1202993. Oncogene. 1999. PMID: 10557094

2

HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. Pietras RJ, et al. Among authors: pegram md. Oncogene. 1995 Jun 15;10(12):2435-46. Oncogene. 1995. PMID: 7784095

3

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Pietras RJ, et al. Among authors: pegram md. Oncogene. 1994 Jul;9(7):1829-38. Oncogene. 1994. PMID: 7911565

4

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. Pegram MD, et al. Oncogene. 1997 Jul 31;15(5):537-47. doi: 10.1038/sj.onc.1201222. Oncogene. 1997. PMID: 9247307

5

Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas.

MacGrogan D, Pegram M, Slamon D, Bookstein R. MacGrogan D, et al. Oncogene. 1997 Aug 28;15(9):1111-4. doi: 10.1038/sj.onc.1201232. Oncogene. 1997. PMID: 9285566

6

Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.

Landgraf R, Pegram M, Slamon DJ, Eisenberg D. Landgraf R, et al. Biochemistry. 1998 Mar 3;37(9):3220-8. doi: 10.1021/bi972326z. Biochemistry. 1998. PMID: 9485477

7

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Pegram MD, et al. J Clin Oncol. 1998 Aug;16(8):2659-71. doi: 10.1200/JCO.1998.16.8.2659. J Clin Oncol. 1998. PMID: 9704716 Clinical Trial.

8

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Pietras RJ, et al. Among authors: pegram md. Oncogene. 1998 Oct 29;17(17):2235-49. doi: 10.1038/sj.onc.1202132. Oncogene. 1998. PMID: 9811454

9

HER-2/neu as a predictive marker of response to breast cancer therapy.

Pegram MD, Pauletti G, Slamon DJ. Pegram MD, et al. Breast Cancer Res Treat. 1998;52(1-3):65-77. doi: 10.1023/a:1006111117877. Breast Cancer Res Treat. 1998. PMID: 10066073 Review.

10

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.

Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Pegram M, et al. Oncogene. 1999 Apr 1;18(13):2241-51. doi: 10.1038/sj.onc.1202526. Oncogene. 1999. PMID: 10327070

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

160 results

Search Page